Selective estrogen receptor-beta (SERM-beta) compounds modulate raphe nuclei tryptophan hydroxylase-1 (TPH-1) mRNA expression and cause antidepressant-like effects in the forced swim test

J. A. Clark, S. Alves, C. Gundlah, B. Rocha, E. T. Birzin, S. J. Cai, R. Flick, E. Hayes, K. Ho, S. Warrier, L. Pai, J. Yudkovitz, R. Fleischer, L. Colwell, S. Li, H. Wilkinson, J. Schaeffer, R. Wilkening, E. Mattingly, M. Hammond & 1 others S. P. Rohrer

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Estrogen acts through two molecularly distinct receptors termed estrogen receptor alpha (ERα) and estrogen receptor beta (ERβ) which bind estradiol with similar affinities and mediate the effects of estrogen throughout the body. ERα plays a major role in reproductive physiology and behavior, and mediates classic estrogen signaling in such tissues as the uterus, mammary gland, and skeleton. ERβ, however, modulates estrogen signaling in the ovary, the immune system, prostate, gastrointestinal tract, and hypothalamus, and there is some evidence that ERβ can regulate ERα activity. Moreover, ERβ knockout studies and receptor distribution analyses in the CNS suggest that this receptor may play a role in the modulation of mood and cognition. In recent years several ERβ-specific compounds (selective estrogen receptor beta modulators; SERM-beta) have become available, and research suggests potential utility of these compounds in menopausal symptom relief, breast cancer prevention, diseases that have an inflammatory component, osteoporosis, cardiovascular disease, and inflammatory bowel disease, as well as modulation of mood, and anxiety. Here we demonstrate an antidepressant-like effect obtained using two SERM-beta compounds, SERM-beta1 and SERM-beta2. These compounds exhibit full agonist activity at ERβ in a cell based estrogen response element (ERE) transactivation assay. SERM-beta1 and 2 are non-proliferative with respect to breast as determined using the MCF-7 breast cancer cell-based assay and non-proliferative in the uterus as determined by assessing the effects of SERM-beta compounds on immature rat uterine weight and murine uterine weight. In vivo SERM-beta1 and 2 are brain penetrant and display dose dependent efficacy in the murine dorsal raphe assays for induction of tryptophan hydroxylase mRNA and progesterone receptor protein. These compounds show activity in the murine forced swim test and promote hippocampal neurogenesis acutely in rats. Taken together these data suggest that ERβ may play an important role in modulating mood and the ERβ specific compounds described herein will be useful tools for probing the utility of an ERβ agonist for treating neuroendocrine-related mood disturbance and menopausal symptoms. Highlights: SERM-beta1 and 2 are selective, non-proliferative, brain penetrant ERβ modulators. SERM-beta compounds modulated the levels of TPH1 mRNA and PR protein in raphe nuclei. SERM-beta compounds promoted neurogenesis and showed antidepressant activity in vivo.

Original languageEnglish
Pages (from-to)1051-1063
Number of pages13
JournalNeuropharmacology
Volume63
Issue number6
DOIs
Publication statusPublished - 11-2012
Externally publishedYes

Fingerprint

Tryptophan Hydroxylase
Selective Estrogen Receptor Modulators
Estrogen Receptor beta
Raphe Nuclei
Estrogen Receptor alpha
Antidepressive Agents
Messenger RNA
Estrogens
Neurogenesis
Uterus
Breast Neoplasms
Weights and Measures
Reproductive Behavior
Estrogen Receptor Modulators
Brain
Response Elements
Progesterone Receptors
Human Mammary Glands
Inflammatory Bowel Diseases
Skeleton

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Cellular and Molecular Neuroscience

Cite this

Clark, J. A. ; Alves, S. ; Gundlah, C. ; Rocha, B. ; Birzin, E. T. ; Cai, S. J. ; Flick, R. ; Hayes, E. ; Ho, K. ; Warrier, S. ; Pai, L. ; Yudkovitz, J. ; Fleischer, R. ; Colwell, L. ; Li, S. ; Wilkinson, H. ; Schaeffer, J. ; Wilkening, R. ; Mattingly, E. ; Hammond, M. ; Rohrer, S. P. / Selective estrogen receptor-beta (SERM-beta) compounds modulate raphe nuclei tryptophan hydroxylase-1 (TPH-1) mRNA expression and cause antidepressant-like effects in the forced swim test. In: Neuropharmacology. 2012 ; Vol. 63, No. 6. pp. 1051-1063.
@article{a16a2caca0de47bc98b225dba23fc448,
title = "Selective estrogen receptor-beta (SERM-beta) compounds modulate raphe nuclei tryptophan hydroxylase-1 (TPH-1) mRNA expression and cause antidepressant-like effects in the forced swim test",
abstract = "Estrogen acts through two molecularly distinct receptors termed estrogen receptor alpha (ERα) and estrogen receptor beta (ERβ) which bind estradiol with similar affinities and mediate the effects of estrogen throughout the body. ERα plays a major role in reproductive physiology and behavior, and mediates classic estrogen signaling in such tissues as the uterus, mammary gland, and skeleton. ERβ, however, modulates estrogen signaling in the ovary, the immune system, prostate, gastrointestinal tract, and hypothalamus, and there is some evidence that ERβ can regulate ERα activity. Moreover, ERβ knockout studies and receptor distribution analyses in the CNS suggest that this receptor may play a role in the modulation of mood and cognition. In recent years several ERβ-specific compounds (selective estrogen receptor beta modulators; SERM-beta) have become available, and research suggests potential utility of these compounds in menopausal symptom relief, breast cancer prevention, diseases that have an inflammatory component, osteoporosis, cardiovascular disease, and inflammatory bowel disease, as well as modulation of mood, and anxiety. Here we demonstrate an antidepressant-like effect obtained using two SERM-beta compounds, SERM-beta1 and SERM-beta2. These compounds exhibit full agonist activity at ERβ in a cell based estrogen response element (ERE) transactivation assay. SERM-beta1 and 2 are non-proliferative with respect to breast as determined using the MCF-7 breast cancer cell-based assay and non-proliferative in the uterus as determined by assessing the effects of SERM-beta compounds on immature rat uterine weight and murine uterine weight. In vivo SERM-beta1 and 2 are brain penetrant and display dose dependent efficacy in the murine dorsal raphe assays for induction of tryptophan hydroxylase mRNA and progesterone receptor protein. These compounds show activity in the murine forced swim test and promote hippocampal neurogenesis acutely in rats. Taken together these data suggest that ERβ may play an important role in modulating mood and the ERβ specific compounds described herein will be useful tools for probing the utility of an ERβ agonist for treating neuroendocrine-related mood disturbance and menopausal symptoms. Highlights: SERM-beta1 and 2 are selective, non-proliferative, brain penetrant ERβ modulators. SERM-beta compounds modulated the levels of TPH1 mRNA and PR protein in raphe nuclei. SERM-beta compounds promoted neurogenesis and showed antidepressant activity in vivo.",
author = "Clark, {J. A.} and S. Alves and C. Gundlah and B. Rocha and Birzin, {E. T.} and Cai, {S. J.} and R. Flick and E. Hayes and K. Ho and S. Warrier and L. Pai and J. Yudkovitz and R. Fleischer and L. Colwell and S. Li and H. Wilkinson and J. Schaeffer and R. Wilkening and E. Mattingly and M. Hammond and Rohrer, {S. P.}",
year = "2012",
month = "11",
doi = "10.1016/j.neuropharm.2012.07.004",
language = "English",
volume = "63",
pages = "1051--1063",
journal = "Neuropharmacology",
issn = "0028-3908",
publisher = "Elsevier Limited",
number = "6",

}

Clark, JA, Alves, S, Gundlah, C, Rocha, B, Birzin, ET, Cai, SJ, Flick, R, Hayes, E, Ho, K, Warrier, S, Pai, L, Yudkovitz, J, Fleischer, R, Colwell, L, Li, S, Wilkinson, H, Schaeffer, J, Wilkening, R, Mattingly, E, Hammond, M & Rohrer, SP 2012, 'Selective estrogen receptor-beta (SERM-beta) compounds modulate raphe nuclei tryptophan hydroxylase-1 (TPH-1) mRNA expression and cause antidepressant-like effects in the forced swim test', Neuropharmacology, vol. 63, no. 6, pp. 1051-1063. https://doi.org/10.1016/j.neuropharm.2012.07.004

Selective estrogen receptor-beta (SERM-beta) compounds modulate raphe nuclei tryptophan hydroxylase-1 (TPH-1) mRNA expression and cause antidepressant-like effects in the forced swim test. / Clark, J. A.; Alves, S.; Gundlah, C.; Rocha, B.; Birzin, E. T.; Cai, S. J.; Flick, R.; Hayes, E.; Ho, K.; Warrier, S.; Pai, L.; Yudkovitz, J.; Fleischer, R.; Colwell, L.; Li, S.; Wilkinson, H.; Schaeffer, J.; Wilkening, R.; Mattingly, E.; Hammond, M.; Rohrer, S. P.

In: Neuropharmacology, Vol. 63, No. 6, 11.2012, p. 1051-1063.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Selective estrogen receptor-beta (SERM-beta) compounds modulate raphe nuclei tryptophan hydroxylase-1 (TPH-1) mRNA expression and cause antidepressant-like effects in the forced swim test

AU - Clark, J. A.

AU - Alves, S.

AU - Gundlah, C.

AU - Rocha, B.

AU - Birzin, E. T.

AU - Cai, S. J.

AU - Flick, R.

AU - Hayes, E.

AU - Ho, K.

AU - Warrier, S.

AU - Pai, L.

AU - Yudkovitz, J.

AU - Fleischer, R.

AU - Colwell, L.

AU - Li, S.

AU - Wilkinson, H.

AU - Schaeffer, J.

AU - Wilkening, R.

AU - Mattingly, E.

AU - Hammond, M.

AU - Rohrer, S. P.

PY - 2012/11

Y1 - 2012/11

N2 - Estrogen acts through two molecularly distinct receptors termed estrogen receptor alpha (ERα) and estrogen receptor beta (ERβ) which bind estradiol with similar affinities and mediate the effects of estrogen throughout the body. ERα plays a major role in reproductive physiology and behavior, and mediates classic estrogen signaling in such tissues as the uterus, mammary gland, and skeleton. ERβ, however, modulates estrogen signaling in the ovary, the immune system, prostate, gastrointestinal tract, and hypothalamus, and there is some evidence that ERβ can regulate ERα activity. Moreover, ERβ knockout studies and receptor distribution analyses in the CNS suggest that this receptor may play a role in the modulation of mood and cognition. In recent years several ERβ-specific compounds (selective estrogen receptor beta modulators; SERM-beta) have become available, and research suggests potential utility of these compounds in menopausal symptom relief, breast cancer prevention, diseases that have an inflammatory component, osteoporosis, cardiovascular disease, and inflammatory bowel disease, as well as modulation of mood, and anxiety. Here we demonstrate an antidepressant-like effect obtained using two SERM-beta compounds, SERM-beta1 and SERM-beta2. These compounds exhibit full agonist activity at ERβ in a cell based estrogen response element (ERE) transactivation assay. SERM-beta1 and 2 are non-proliferative with respect to breast as determined using the MCF-7 breast cancer cell-based assay and non-proliferative in the uterus as determined by assessing the effects of SERM-beta compounds on immature rat uterine weight and murine uterine weight. In vivo SERM-beta1 and 2 are brain penetrant and display dose dependent efficacy in the murine dorsal raphe assays for induction of tryptophan hydroxylase mRNA and progesterone receptor protein. These compounds show activity in the murine forced swim test and promote hippocampal neurogenesis acutely in rats. Taken together these data suggest that ERβ may play an important role in modulating mood and the ERβ specific compounds described herein will be useful tools for probing the utility of an ERβ agonist for treating neuroendocrine-related mood disturbance and menopausal symptoms. Highlights: SERM-beta1 and 2 are selective, non-proliferative, brain penetrant ERβ modulators. SERM-beta compounds modulated the levels of TPH1 mRNA and PR protein in raphe nuclei. SERM-beta compounds promoted neurogenesis and showed antidepressant activity in vivo.

AB - Estrogen acts through two molecularly distinct receptors termed estrogen receptor alpha (ERα) and estrogen receptor beta (ERβ) which bind estradiol with similar affinities and mediate the effects of estrogen throughout the body. ERα plays a major role in reproductive physiology and behavior, and mediates classic estrogen signaling in such tissues as the uterus, mammary gland, and skeleton. ERβ, however, modulates estrogen signaling in the ovary, the immune system, prostate, gastrointestinal tract, and hypothalamus, and there is some evidence that ERβ can regulate ERα activity. Moreover, ERβ knockout studies and receptor distribution analyses in the CNS suggest that this receptor may play a role in the modulation of mood and cognition. In recent years several ERβ-specific compounds (selective estrogen receptor beta modulators; SERM-beta) have become available, and research suggests potential utility of these compounds in menopausal symptom relief, breast cancer prevention, diseases that have an inflammatory component, osteoporosis, cardiovascular disease, and inflammatory bowel disease, as well as modulation of mood, and anxiety. Here we demonstrate an antidepressant-like effect obtained using two SERM-beta compounds, SERM-beta1 and SERM-beta2. These compounds exhibit full agonist activity at ERβ in a cell based estrogen response element (ERE) transactivation assay. SERM-beta1 and 2 are non-proliferative with respect to breast as determined using the MCF-7 breast cancer cell-based assay and non-proliferative in the uterus as determined by assessing the effects of SERM-beta compounds on immature rat uterine weight and murine uterine weight. In vivo SERM-beta1 and 2 are brain penetrant and display dose dependent efficacy in the murine dorsal raphe assays for induction of tryptophan hydroxylase mRNA and progesterone receptor protein. These compounds show activity in the murine forced swim test and promote hippocampal neurogenesis acutely in rats. Taken together these data suggest that ERβ may play an important role in modulating mood and the ERβ specific compounds described herein will be useful tools for probing the utility of an ERβ agonist for treating neuroendocrine-related mood disturbance and menopausal symptoms. Highlights: SERM-beta1 and 2 are selective, non-proliferative, brain penetrant ERβ modulators. SERM-beta compounds modulated the levels of TPH1 mRNA and PR protein in raphe nuclei. SERM-beta compounds promoted neurogenesis and showed antidepressant activity in vivo.

UR - http://www.scopus.com/inward/record.url?scp=84865274050&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84865274050&partnerID=8YFLogxK

U2 - 10.1016/j.neuropharm.2012.07.004

DO - 10.1016/j.neuropharm.2012.07.004

M3 - Article

VL - 63

SP - 1051

EP - 1063

JO - Neuropharmacology

JF - Neuropharmacology

SN - 0028-3908

IS - 6

ER -